Abstract:Abstract Background: Gene mutations and copy number variations (CNVs) are associated with the occurrence and development of tumors. Neoadjuvant therapy (NAT) has shown greater clinical benefit in the treatment of HER2-positive breast cancer (BC). The impact of genetic mutations on NAT efficacy in BC has been frequently reported, but the relationship between genetic mutations and NAT efficacy and the long-term prognosis in HER2-positive BC patients still requires more high-quality studies. Methods: This retrospective cohort study was conducted patients receiving NAT between September 2017 and March 2021 in the Department of Breast Surgery of Fudan University Shanghai Cancer Center (FUSCC). The genomic characteristics of 513 cancer-related genes from the archived tumour blocks were assessed by next-generation sequencing (NGS). The relationship between tumour mutated gene and the postoperative pathological complete response (pCR) as well as prognosis of the disease-free survival (DFS) were further explored.Statistical methods included Chi-square test, fisher's exact test, Kaplan-Meier survival analysis, all of which were completed by SPSS 20.0. Results: 208(47.8%) patients achieved pCR after HER2-targeted NAT and 40(9.2%) patients encountered DFS events. The frequency of somatic alterations in TP53(60%), PIK3CA (15%) and ERBB2(11%) was highest in women with HER2-positive breast cancer. KMT2C (P= 0.036) and TP53(P=0.037) mutations were significantly increased in patients with DFS events. In the HER2+/HR- cohort, patients who achieved pCR had significantly benefit in prognosis (HR=3.605, P=0.002), and CCND1 amplifications(p=0.014), ATM(p=0.016) and GATA3(p=0.016) mutations were more frequent. ERBB2 mutations were significantly associated with younger ages of diagnosis(p=0.018). TP53 mutations were associated with worse DFS (HR=3.242, P=0.0110) as well as more DFS events(p=0.048). Furthermore, TP53 mutations had significant prognostic importance in HER2-positive BC patients with HR-negative (HR=3.712, P=0.0266), pCR (HR=6.253, P=0.0268) and who received trastuzumab-only targeted therapy (HR=4.145, P=0.0105). Conclusions: Regard to diverse hormone receptor status or neoadjuvant efficacy, the genetic mutation maps of Chinese HER2+ patients receiving NAT are disparate. Our study found that TP53 mutations have significant prognostic value in patients with NAT for HER2-positive BC and patients benefit differently depending on HR status, neoadjuvant regimens and response. Citation Format: Min Xiong, Liren Wangxu, Jingyan Xue, Benlong Yang, Jiong Wu. Somatic mutations of a multigene panel in Chinese HER2-positive patients undergoing neoadjuvant therapy and impact on prognosis based on TP53 status:a single-institution retrospective cohort [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO3-08-10.

Abstract P3-03-08: Not Presented

Abstract P3-03-13: Not Presented

Abstract P3-04-02: Not presented

Abstract P4-08-18: Not Presented

Abstract P4-15-03: Not Presented

P1119 Comparative Study of Neoadjuvant Intravenous Versus Intraarterial Chemotherapy Versus Brachytherapy Followed by Radical Surgery Versus Radical Surgery Alone in Stage IB2–IIA Bulky Cervical Cancers: a Phase III Randomized Clinical Trial in Shanghai

Abstract P1-10-10: Risk factors of locoregional recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes

Plenary Paper

Abstract P5-16-07: Non-anthracycline-containing Docetaxel Plus Cyclophosphomide Was Inferior to Docetaxel, Anthracycline and Cyclophosphomide in Neoadjuvant Treatment of Triple Negative or HER2 Positive Breast Cancer: Long Term Follow-Up Result from NATT Study

Abstract C146: Racial and Ethnic Differences in the Biological Signatures of Breast Tumors and the Immune-microenvironment: The Multiethnic Cohort Study

Abstract B153: Social and Structural Influences of Preventive Cancer Screenings for Native Hawaiian and Pacific Islander Adults in Hawaiʻi

Abstract P3-04-14: Zoledronic Acid Sensitized Breast Cancer Cells to Fulvestrant Via ERK/FOXO3a/HIF-1 Α Inhibition Through Nuclear FOXO3a Translocation

Abstract A078: Cancer Incidence in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) – The Onco-SOL Ancillary Study

Abstract B145: County-level food insecurity and hepatocellular carcinoma risk: A cross-sectional analysis

Abstract C107: Differential gene expression analysis comparing Black and White patients with HPV-positive oropharyngeal squamous cell carcinoma reveals suppressed immune response and higher rates P16/HPV DNA discordance in Black patients

Abstract C136: Impact of the Affordable Care Act on receipt of guideline-concordant care for colon cancer

Abstract A067: Increasing risk of prostate cancer with successive generations in the US among Latino men in the Multiethnic Cohort

Abstract A073: Gut microbiome differences across race, ethnicity, and area level deprivation among patients undergoing colorectal cancer screening in Federally Qualified Health Centers

RETRACTED: ORIENT-3: A Randomized, Open-Label, Phase III Study of Sintilimab Versus Docetaxel in Previously Treated Advanced/metastatic Squamous Non-Small Cell Lung Cancer (Sqnsclc)

Abstract C079: Investigating the interplay among allostatic load, social determinants of health, and treatment outcomes in chronic myeloid leukemia patients

Abstract PO3-08-10: Somatic Mutations of a Multigene Panel in Chinese HER2-positive Patients Undergoing Neoadjuvant Therapy and Impact on Prognosis Based on TP53 Status:A Single-Institution Retrospective Cohort